tiprankstipranks
Thermo Fisher Scientific (DE:TN8)
NYSE:TN8
Germany Market
TN8
Thermo Fisher
RESEARCH TOOLSreports

Thermo Fisher (TN8) Stock Forecast & Price Target

8 Followers
See the Price Targets and Ratings of:

TN8 Analyst Ratings

Strong Buy
21Ratings
Strong Buy
16 Buy
5 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Thermo
Fisher
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TN8 Stock 12 Month Forecast

Average Price Target

€518.53
▲(15.56% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Thermo Fisher in the last 3 months. The average price target is €518.53 with a high forecast of €601.23 and a low forecast of €430.08. The average price target represents a 15.56% change from the last price of €448.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"345":"€345","602":"€602","409.25":"€409.3","473.5":"€473.5","537.75":"€537.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":601.22738385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€601.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":518.5281427299999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€518.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430.0750629,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€430.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[345,409.25,473.5,537.75,602],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.379,437.9827218346154,451.5864436692308,465.1901655038462,478.79388733846156,492.39760917307694,506.00133100769233,519.6050528423077,533.2087746769231,546.8124965115385,560.4162183461539,574.0199401807693,587.6236620153846,{"y":601.22738385,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.379,431.62124174846156,438.8634834969231,446.10572524538463,453.3479669938461,460.59020874230765,467.8324504907692,475.0746922392307,482.31693398769227,489.55917573615375,496.8014174846153,504.0436592330768,511.28590098153836,{"y":518.5281427299999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.379,424.8171586846154,425.2553173692308,425.69347605384615,426.13163473846157,426.56979342307693,427.0079521076923,427.4461107923077,427.88426947692307,428.3224281615384,428.76058684615384,429.1987455307692,429.6369042153846,{"y":430.0750629,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":346.332,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":358.649,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":393.025,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":416.041,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":440.794,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":488.065,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":506.315,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":492.971,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.578,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":431.693,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":428.425,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405.797,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.379,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€601.23Average Price Target€518.53Lowest Price Target€430.08
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:TN8
Eve Burstein
Bernstein
Bernstein
€456.41
Hold
1.72%
Upside
Assigned
06/25/26
Thermo Fisher resumed with a Market Perform at BernsteinThermo Fisher resumed with a Market Perform at Bernstein
Barclays Analyst forecast on DE:TN8
Luke Sergott
Barclays
Barclays
€548.57
Buy
22.26%
Upside
Reiterated
06/24/26
Barclays Sticks to Their Buy Rating for Thermo Fisher (TMO)
William Blair Analyst forecast on DE:TN8
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on DE:TN8
David Westenberg
Piper Sandler
Piper Sandler
€447.63
Hold
-0.24%
Downside
Initiated
06/11/26
Thermo Fisher initiated with a Neutral at Piper SandlerThermo Fisher initiated with a Neutral at Piper Sandler
HSBC Analyst forecast on DE:TN8
Sidharth Sahoo
HSBC
HSBC
€588.06→€473.96
Hold
5.63%
Upside
Downgraded
06/03/26
Thermo Fisher downgraded to Hold from Buy at HSBCThermo Fisher downgraded to Hold from Buy at HSBC
Bank of America Securities Analyst forecast on DE:TN8
Michael Ryskin
Bank of America Securities
Bank of America Securities
€552.95
Buy
23.23%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Thermo Fisher (NYSE: TMO)
Wolfe Research Analyst forecast on DE:TN8
Michael Polark
Wolfe Research
Wolfe Research
€469.57
Buy
4.65%
Upside
Initiated
06/01/26
Thermo Fisher assumed with an Outperform at Wolfe ResearchThermo Fisher assumed with an Outperform at Wolfe Research
Jefferies Analyst forecast on DE:TN8
Tycho Peterson
Jefferies
Jefferies
€570.51
Buy
27.15%
Upside
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Thermo Fisher (NYSE: TMO) and Eli Lilly & Co (NYSE: LLY)
Wells Fargo Analyst forecast on DE:TN8
Brandon Couillard
Wells Fargo
Wells Fargo
€539.79
Buy
20.30%
Upside
Assigned
05/21/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:TN8
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€526.62
Buy
17.37%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Thermo Fisher (NYSE: TMO)
TD Cowen Analyst forecast on DE:TN8
Daniel Brennan
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/20/26
Analysts' Top Healthcare Picks: Thermo Fisher (TMO), Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
RBC Capital Analyst forecast on DE:TN8
Dan Leonard
RBC Capital
RBC Capital
€430.08
Hold
-4.15%
Downside
Initiated
05/14/26
Thermo Fisher resumed with a Sector Perform at RBC CapitalThermo Fisher resumed with a Sector Perform at RBC Capital
Erste Group Analyst forecast on DE:TN8
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pediatrix Medical Group (NYSE: MD)
Argus Research Analyst forecast on DE:TN8
Bill Selesky
Argus Research
Argus Research
€535.4→€491.51
Buy
9.54%
Upside
Reiterated
04/30/26
Argus Research Reaffirms Their Buy Rating on Thermo Fisher (TMO)
CMB International Securities Analyst forecast on DE:TN8
Jill Wu
CMB International Securities
CMB International Securities
€588.06→€544.18
Buy
21.28%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on DE:TN8
Eve Burstein
Bernstein
Bernstein
€456.41
Hold
1.72%
Upside
Assigned
06/25/26
Thermo Fisher resumed with a Market Perform at BernsteinThermo Fisher resumed with a Market Perform at Bernstein
Barclays Analyst forecast on DE:TN8
Luke Sergott
Barclays
Barclays
€548.57
Buy
22.26%
Upside
Reiterated
06/24/26
Barclays Sticks to Their Buy Rating for Thermo Fisher (TMO)
William Blair Analyst forecast on DE:TN8
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on DE:TN8
David Westenberg
Piper Sandler
Piper Sandler
€447.63
Hold
-0.24%
Downside
Initiated
06/11/26
Thermo Fisher initiated with a Neutral at Piper SandlerThermo Fisher initiated with a Neutral at Piper Sandler
HSBC Analyst forecast on DE:TN8
Sidharth Sahoo
HSBC
HSBC
€588.06→€473.96
Hold
5.63%
Upside
Downgraded
06/03/26
Thermo Fisher downgraded to Hold from Buy at HSBCThermo Fisher downgraded to Hold from Buy at HSBC
Bank of America Securities Analyst forecast on DE:TN8
Michael Ryskin
Bank of America Securities
Bank of America Securities
€552.95
Buy
23.23%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Thermo Fisher (NYSE: TMO)
Wolfe Research Analyst forecast on DE:TN8
Michael Polark
Wolfe Research
Wolfe Research
€469.57
Buy
4.65%
Upside
Initiated
06/01/26
Thermo Fisher assumed with an Outperform at Wolfe ResearchThermo Fisher assumed with an Outperform at Wolfe Research
Jefferies Analyst forecast on DE:TN8
Tycho Peterson
Jefferies
Jefferies
€570.51
Buy
27.15%
Upside
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Thermo Fisher (NYSE: TMO) and Eli Lilly & Co (NYSE: LLY)
Wells Fargo Analyst forecast on DE:TN8
Brandon Couillard
Wells Fargo
Wells Fargo
€539.79
Buy
20.30%
Upside
Assigned
05/21/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:TN8
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
€526.62
Buy
17.37%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Thermo Fisher (NYSE: TMO)
TD Cowen Analyst forecast on DE:TN8
Daniel Brennan
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/20/26
Analysts' Top Healthcare Picks: Thermo Fisher (TMO), Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
RBC Capital Analyst forecast on DE:TN8
Dan Leonard
RBC Capital
RBC Capital
€430.08
Hold
-4.15%
Downside
Initiated
05/14/26
Thermo Fisher resumed with a Sector Perform at RBC CapitalThermo Fisher resumed with a Sector Perform at RBC Capital
Erste Group Analyst forecast on DE:TN8
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Vertex Pharmaceuticals (NASDAQ: VRTX) and Pediatrix Medical Group (NYSE: MD)
Argus Research Analyst forecast on DE:TN8
Bill Selesky
Argus Research
Argus Research
€535.4→€491.51
Buy
9.54%
Upside
Reiterated
04/30/26
Argus Research Reaffirms Their Buy Rating on Thermo Fisher (TMO)
CMB International Securities Analyst forecast on DE:TN8
Jill Wu
CMB International Securities
CMB International Securities
€588.06→€544.18
Buy
21.28%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Thermo Fisher

3 Months
Daniel AriasStifel Nicolaus
Success Rate
18/26 ratings generated profit
69%
Average Return
+2.01%
Copying Daniel Arias's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +2.01% per trade.
1 Year
Sung Ji NamScotiabank
Success Rate
16/19 ratings generated profit
84%
Average Return
+15.75%
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +15.75% per trade.
2 Years
Sung Ji NamScotiabank
Success Rate
16/19 ratings generated profit
84%
Average Return
+31.96%
Copying Sung Ji Nam's trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +31.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TN8 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
25
20
22
28
30
Hold
1
1
1
3
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
21
23
31
36
In the current month, TN8 has received 30 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TN8 average Analyst price target in the past 3 months is 518.53.
Each month's total comprises the sum of three months' worth of ratings.

TN8 Financial Forecast

TN8 Earnings Forecast

Next quarter’s earnings estimate for TN8 is €4.95 with a range of €4.89 to €5.01. The previous quarter’s EPS was €4.71. TN8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TN8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for TN8 is €4.95 with a range of €4.89 to €5.01. The previous quarter’s EPS was €4.71. TN8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TN8 has Performed in-line its overall industry.

TN8 Sales Forecast

Next quarter’s sales forecast for TN8 is €10.13B with a range of €9.93B to €10.25B. The previous quarter’s sales results were €9.53B. TN8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TN8 has Performed in-line its overall industry.
Next quarter’s sales forecast for TN8 is €10.13B with a range of €9.93B to €10.25B. The previous quarter’s sales results were €9.53B. TN8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TN8 has Performed in-line its overall industry.

TN8 Stock Forecast FAQ

What is DE:TN8’s average 12-month price target, according to analysts?
Based on analyst ratings, Thermo Fisher Scientific’s 12-month average price target is 518.53.
    What is DE:TN8’s upside potential, based on the analysts’ average price target?
    Thermo Fisher Scientific has 15.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Thermo Fisher Scientific a Buy, Sell or Hold?
          Thermo Fisher Scientific has a consensus rating of Strong Buy, which is based on 16 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Thermo Fisher Scientific’s share price target?
            The average share price target for Thermo Fisher Scientific is 518.53. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €601.23 ,and the lowest forecast is €430.08. The average share price target represents 15.56% Increase from the current price of €448.7.
              What do analysts say about Thermo Fisher Scientific?
              Thermo Fisher Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Thermo Fisher Scientific?
                To buy shares of DE:TN8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.